apx-115
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 28, 2018 (NCT03694041)
Timeline
Indications
Mechanism of action
- Cytochrome b-245 heavy chainINHIBITOR
CYBB inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCc1c(-c2ccccc2)nn(-c2ccccn2)c1O- Mol. weight
- 279.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650894 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06962098 | Phase 2 | May 26, 2025 | Aptabio Therapeutics, Inc. |
| NCT05758896 | Phase 2 | Jul 31, 2023 | Aptabio Therapeutics, Inc. |
| NCT04880109 | Phase 2 | Oct 20, 2021 | Aptabio Therapeutics, Inc., Covance |
| NCT04534439 | Phase 2 | Aug 24, 2020 | Aptabio Therapeutics, Inc., University of Pecs |
| NCT03694041 | Phase 1 | May 28, 2018 | Aptabio Therapeutics, Inc., Eurofins |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptabio Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2018 |
| Covance | For profit | 1 | 0 | 1 | 2021 |
| Eurofins | For profit | 1 | 0 | 1 | 2018 |
| University of Pecs | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1